Loading...
Please wait, while we are loading the content...
Similar Documents
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Dasbach, Erik J. Insinga, Ralph P. Elbasha, Elamin H. |
| Copyright Year | 2008 |
| Abstract | OBJECTIVE To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts. DESIGN Cost-utility analysis. SETTING UK. POPULATION Female and male UK population 12 years or older. METHODS We adapted a previously developed multi-HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch-up vaccination at ages 12-14, 12-17 and 12-24 years. MAIN OUTCOMES MEASURES Costs, cases avoided, incremental cost per quality-adjusted life year (QALY). RESULTS The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18-related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccination at age 12 years combined with a 12- to 24-year-old catch-up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2/3, CIN1 and genital warts by 5800, 146 000, 28 000, and 1.1 million respectively. Over 100 years, the incremental cost-effectiveness ratios across all strategies ranged from pound5882 to pound11,412 per QALY gained. CONCLUSION In the UK, a quadrivalent HPV vaccination programme that includes a catch-up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost-effective. |
| File Format | PDF HTM / HTML |
| DOI | 10.1111/j.1471-0528.2008.01743.x |
| PubMed reference number | 18503574 |
| Journal | Medline |
| Volume Number | 115 |
| Issue Number | 8 |
| Alternate Webpage(s) | https://www.crd.york.ac.uk/CRDWeb/PrintPDF.php?AccessionNumber=22008101290&AccessionNumber=22008101290&Copyright=NHS+Economic+Evaluation+Database+(NHS+EED)%3Cbr+/%3EProduced+by+the+Centre+for+Reviews+and+Dissemination+%3Cbr+/%3ECopyright+%26copy%3B+2016+University+of+York%3Cbr+/%3E&Copyright=NHS+Economic+Evaluation+Database+(NHS+EED)%3Cbr+/%3EProduced+by+the+Centre+for+Reviews+and+Dissemination+%3Cbr+/%3ECopyright+%26copy%3B+2016+University+of+York%3Cbr+/%3E |
| Alternate Webpage(s) | http://www.crd.york.ac.uk/CRDWeb/PrintPDF.php?AccessionNumber=22008101290&Copyright=NHS+Economic+Evaluation+Database+(NHS+EED)%3Cbr+/%3EProduced+by+the+Centre+for+Reviews+and+Dissemination+%3Cbr+/%3ECopyright+%26copy%3B+2017+University+of+York%3Cbr+/%3E |
| Journal | BJOG : an international journal of obstetrics and gynaecology |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
